TransCode Therapeutics公司与Quantum Leap共同宣布,已正式提交针对TTX-MC138药物的二期a阶段临床试验新药研究申请修正案。该举措标志着双方在推进创新疗法临床开发方面取得重要进展。
TransCode Therapeutics公司与Quantum Leap共同宣布,已正式提交针对TTX-MC138药物的二期a阶段临床试验新药研究申请修正案。该举措标志着双方在推进创新疗法临床开发方面取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.